Molecular mechanisms of rhodopsin retinitis pigmentosa and the efficacy of pharmacological rescue.
Variants of rhodopsin, a complex of 11-cis retinal and opsin, cause retinitis pigmentosa (RP), a degenerative disease of the retina. Trafficking defects due to rhodopsin misfolding have been proposed as the most likely basis of the disease, but other potentially overlapping mechanisms may also apply. Pharmacological therapies for RP must target the major disease mechanism and contend with overlap, if it occurs. To this end, we have explored the molecular basis of rhodopsin RP in the context of pharmacological rescue with 11-cis retinal. Stable inducible cell lines were constructed to express wild-type opsin; the pathogenic variants T4R, T17M, P23A, P23H, P23L, and C110Y; or the nonpathogenic variants F220L and A299S. Pharmacological rescue was measured as the fold increase in rhodopsin or opsin levels upon addition of 11-cis retinal during opsin expression. Only Pro23 and T17M variants were rescued significantly. C110Y opsin was produced at low levels and did not yield rhodopsin, whereas the T4R, F220L, and A299S proteins reached near-wild-type levels and changed little with 11-cis retinal. All of the mutant rhodopsins exhibited misfolding, which increased over a broad range in the order F220L, A299S, T4R, T17M, P23A, P23H, P23L, as determined by decreased thermal stability in the dark and increased hydroxylamine sensitivity. Pharmacological rescue increased as misfolding decreased, but was limited for the least misfolded variants. Significantly, pathogenic variants also showed abnormal photobleaching behavior, including an increased ratio of metarhodopsin-I-like species to metarhodopsin-II-like species and aberrant photoproduct accumulation with prolonged illumination. These results, combined with an analysis of published biochemical and clinical studies, suggest that many rhodopsin variants cause disease by affecting both biosynthesis and photoactivity. We conclude that pharmacological rescue is promising as a broadly effective therapy for rhodopsin RP, particularly if implemented in a way that minimizes the photoactivity of the mutant proteins.
Krebs
Mark P
MP
Department of Ophthalmology and the Charlie Mack Overstreet Laboratories for Retinal Diseases, College of Medicine, University of Florida, Gainesville, FL 32610, USA.
Holden
David C
DC
Joshi
Parth
P
Clark
Charles L
CL
Lee
Andrew H
AH
Kaushal
Shalesh
S
D019943:Amino Acid Substitution; D000818:Animals; D001483:Base Sequence; D002417:Cattle; D002460:Cell Line; D017931:DNA Primers / Q000235:genetics; D014644:Genetic Variation; D006801:Humans; D019811:Hydroxylamine / Q000494:pharmacology; D066298:In Vitro Techniques; D050505:Mutant Proteins / Q000737:chemistry / Q000235:genetics* / Q000378:metabolism*; D009154:Mutation; D055355:Opsins / Q000737:chemistry / Q000378:metabolism; D038761:Photobleaching; D017510:Protein Folding / Q000187:drug effects; D055550:Protein Stability; D011994:Recombinant Proteins / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D012172:Retinaldehyde / Q000494:pharmacology; D012174:Retinitis Pigmentosa / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism*; D012243:Rhodopsin / Q000737:chemistry / Q000235:genetics* / Q000378:metabolism*
D017931:DNA Primers; D050505:Mutant Proteins; D055355:Opsins; D011994:Recombinant Proteins; D019811:Hydroxylamine; D012243:Rhodopsin; D012172:Retinaldehyde